Answers are grounded in this paper and cite their sources.
Human study investigates glycine's role on auditory processing in schizophrenia, suggesting potential biomarkers for treatment.
This is the first study in humans to investigate the effects of glycine on the MMN in the ketamine model of schizophrenia. The results confirm a key role of the glutamate system for pre-attentive auditory processing deficits underlying the symptoms of schizophrenia. From a translational perspective, the MMN and its theta-band signature may serve as biomarkers to identify patients who may benefit from glutamatergic treatment options.
No takes yet. Share an insight, caveat, or question.
Ćurić et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: